



**HAL**  
open science

## Neuropsychological functioning, age, and medication adherence in bipolar disorder

Nadia Corréard, Julia-Lou Consoloni, Aurélie Raust, Bruno Etain, Romain Guillot, Sophie Job, Joséphine Loftus, Isabelle Médecin, Thierry Bougerol, Mircea Polosan, et al.

► **To cite this version:**

Nadia Corréard, Julia-Lou Consoloni, Aurélie Raust, Bruno Etain, Romain Guillot, et al.. Neuropsychological functioning, age, and medication adherence in bipolar disorder. PLoS ONE, 2017, 12 (9), 10.1371/journal.pone.0184313 . hal-01676202

**HAL Id: hal-01676202**

**<https://hal.science/hal-01676202v1>**

Submitted on 25 May 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH ARTICLE

# Neuropsychological functioning, age, and medication adherence in bipolar disorder

Nadia Corréard<sup>1,2</sup>, Julia-Lou Consoloni<sup>1,2,3</sup>, Aurélie Raust<sup>2,4</sup>, Bruno Etain<sup>2,5</sup>, Romain Guillot<sup>2,6</sup>, Sophie Job<sup>2,6</sup>, Joséphine Loftus<sup>2,7</sup>, Isabelle Médecin<sup>2,7</sup>, Thierry Bougerol<sup>2,8</sup>, Mircea Polosan<sup>2,8,9</sup>, Benjamin Fredembach<sup>2,8</sup>, Sébastien Gard<sup>2,10</sup>, Katia M'Bailara<sup>2,10,11</sup>, Jean-Pierre Kahn<sup>2,6,12,13</sup>, Paul Roux<sup>2,14</sup>, Anne-Sophie Homassel<sup>2,14</sup>, Mathilde Carminati<sup>2,5</sup>, Lucile Matos<sup>2,15</sup>, Emilie Olié<sup>2,15,16</sup>, Frank Bellivier<sup>2,5</sup>, Philippe Courtet<sup>2,15,16</sup>, Chantal Henry<sup>2,4,17</sup>, Marion Leboyer<sup>2,4,17</sup>, Jean-Michel Azorin<sup>1,2,18</sup>, Raoul Belzeaux<sup>1,2,3\*</sup>, FACE-BD collaborators<sup>†</sup>


**1** Department of Psychiatry, AP-HM, Marseille, France, **2** FondaMental foundation, Foundation of scientific cooperation, Créteil, France, **3** CRN2M-UMR7286, Aix-Marseille University, CNRS, Marseille, France, **4** AP-HP, Academic Hospital Henri Mondor, Psychiatric and Addictology pole, Créteil, France, **5** AP-HP, Fernand Widal Hospital, Department of Addictology-Toxicology-Psychiatry and University Paris-7, Paris, France, **6** Department of Psychiatry and Clinical Psychology, Psychotherapeutic Centre of Nancy, Laxou, France, **7** Department of Psychiatry, Princess-Grace Hospital, Monaco, Monaco, **8** Department of Psychiatry, Academic Hospital of Grenoble, Grenoble, France, **9** U1216 INSERM-UGA – Brain stimulation and Systems neuroscience, Grenoble Institute of Neurosciences, La Tronche, France, **10** Charles-Perrens Hospital, Department of clinical and academic Psychiatry, Bordeaux, France, **11** University of Bordeaux, Laboratory of psychology, Bordeaux, France, **12** French Addictovigilance network (CEIP-A) CHRU of Nancy, Nancy, France, **13** University of Lorraine, Nancy, France, **14** Department of Psychiatry for adults, Academic Hospital of Versailles, UFR of Health Sciences Simone Veil, University of Versailles Saint-Quentin en Yvelines, Versailles, France, **15** CHRU Lapeyronie, Department of Emergency Psychiatry and Post-Acute Care, Montpellier, France, **16** Inserm, U1061, University of Montpellier, Montpellier, France, **17** Inserm, U955, Translational Psychiatry, Mondor Institute, Créteil, France, **18** CNRS, UMR 7289, Institute of Neurosciences Timone, Marseille, France

☞ These authors contributed equally to this work.

✉ Current Address: McGill Group for Suicide Studies, Department of Psychiatry, McGill University, Douglas Mental Health University Institute, Montreal, Québec, Canada.

† Membership of the FACE-BD (FondaMental Advanced Centres of Expertise – Bipolar Disorders) collaborators is provided in the Acknowledgments.

\* [raoul.belzeaux@ap-hm.fr](mailto:raoul.belzeaux@ap-hm.fr)



OPEN ACCESS

**Citation:** Corréard N, Consoloni J-L, Raust A, Etain B, Guillot R, Job S, et al. (2017) Neuropsychological functioning, age, and medication adherence in bipolar disorder. PLoS ONE 12(9): e0184313. <https://doi.org/10.1371/journal.pone.0184313>

**Editor:** Tadafumi Kato, RIKEN Brain Science Institution, JAPAN

**Received:** March 6, 2017

**Accepted:** August 22, 2017

**Published:** September 5, 2017

**Copyright:** © 2017 Corréard et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Due to ethical and legal restrictions, data involving clinical participants are the property of the FondaMental foundation and cannot be made publicly available. Data are available upon request and after agreement of the scientific committee of the FondaMental Foundation. Researchers who meet the criteria for accessing to confidential data can contact the foundation by sending an e-mail to [face@fondation-fondamental.org](mailto:face@fondation-fondamental.org).

## Abstract

### Objectives

Poor adherence to medication is frequent in bipolar disorder (BD) and has been associated with several factors. To date, the relationship between low adherence and neuropsychological functioning in BD is still unclear. As age and neuropsychological functioning might have opposing influences on adherence, our aim was to investigate this link with a particular focus on the effect of age.

### Methods

In a cross-sectional study, we included 353 patients divided into two age-groups (16–46; 47–71) from a French cohort diagnosed with BD (type I, II, NOS) and strictly euthymic. All patients had a standardized clinical and neuropsychological assessment and were categorized as high (n = 186) or low (n = 167) adherent based on their score from the Medication

**Funding:** This study was financially supported (in part) by the FondaMental foundation (<https://www.fondation-fondamental.org/>) and by the Investissements d'Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02. The 2 first authors (N.C. and J-L.C.) have received the FACE's grant from the FondaMental foundation to conduct their research projects on treatment adherence in bipolar patients. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

Adherence Rating Scale. Clinical information was collected based on a standardized interview and clinical validated scales. Neuropsychological performances were evaluated with an established standardized neuropsychological battery for bipolar disorder patients. After univariate analysis, neuropsychological and clinical predictors of low adherence were included in two age-specific stepwise multiple logistic regressions.

## Results

A smaller number of hospitalizations (OR = 0.846,  $p = 0.012$ ), a shorter illness duration (OR = 0.937,  $p = 0.003$ ) and higher adverse effects (OR = 1.082,  $p < 0.001$ ) were associated with a greater risk of low adherence in the younger patients. In the older patients, low adherence was also predicted by a smaller number of hospitalizations (OR = 0.727,  $p = 0.008$ ) and higher adverse effects (OR = 1.124,  $p = 0.005$ ). Interestingly poor inhibition performance was also a significant predictor of low adherence in older patients (OR = 0.924,  $p = 0.030$ ).

## Conclusions

We found an age-specific relationship between cognitive functioning and adherence in patients with BD. Poor inhibition performances predicted low adherence in older patients only. Our results highlight the need to provide age-adapted therapeutic interventions to improve adherence in patients with BD.

## Introduction

Bipolar disorder (BD) is a chronic and severe mental disorder often characterized by residual symptoms as well as heterogeneous impairment of cognitive functioning [1–3]. Pharmacological treatment is essential to treat symptomatic mood episodes and to prevent relapses and recurrences [4]. Unfortunately, treatment nonadherence is frequent in BD. About 20% to 60% of patients are considered as poor or nonadherent without regard to the phase of the illness, including symptomatic remission periods [5, 6]. Treatment nonadherence has severe consequences. It is associated with more relapses, recurrences and an increased risk of suicide [7, 8]. Several factors have been related to low treatment adherence in BD [5, 6, 9]. We and others have demonstrated that male gender, depressive residual symptoms, and a higher level of medication side effects were associated with treatment nonadherence. Comorbidity such as substance use disorder has also been strongly associated with low treatment adherence in BD [10, 11]. Moreover, an increase in age of patients was linked with increased adherence to medication [9, 12, 13].

Otherwise, non-adherence to medication in chronic illnesses has been divided into two categories by researchers according to the patient's perspective [14, 15]. Intentional non-adherence is defined as an active process whereby the patients voluntarily do not take the prescribed medication (i.e. Stopping or not taking medication or deciding to reduce the posology without informing the doctor) whereas unintentional non-adherence refers to unplanned and unconscious behaviors resulting to non-adherence. Unintentional non-adherence depends on the patients' ability, and factors beyond their control, to follow the medical recommendations especially due to cognitive impairments (i.e. forgetting to take the medication). Therefore, researchers have started to investigate the association between cognitive impairments and medication adherence. An abundant literature has highlighted a link between neurocognitive

dysfunction and treatment adherence in different diseases such as Parkinson disease, lupus erythematosus, and HIV infection [16–18]. Three previous studies have also suggested such an association in BD [19–21], while another study did not find any relationship between adherence and neurocognition [22]. Martinez-Aran et al [19] found that euthymic BD patients with poor adherence showed verbal learning and memory impairments as well as executive impairments in comparison to high adherent patients and healthy controls. As a consequence, to date, this relationship remains poorly studied and the results are still unclear.

Interestingly, on the one hand, age is associated with a decrease of neuropsychological performance across the lifespan of a healthy adult as well as in patients with BD [23–25]. Furthermore, aging worsens the cognitive impairments observed in BD [26]. On the other hand, increasing age is associated with better treatment adherence. Thus, age could be a major confounding factor when analyzing the relationship between adherence and neuropsychological functioning in patients. However, only one previous study examined the hypothesis of an age effect in the relationship between neurocognition and medication adherence, and this concerned patients with HIV infection [27]. In this study, neurocognitive impairment was associated with poorer medication adherence among older participants only. To the best of our knowledge, no previous study has been performed focusing on BD or other psychiatric disorders. A better understanding of the effect of cognitive impairments in BD patients is needed to develop and adapt techniques to improve adherence to medication in these patients and improve their quality of life.


We therefore aimed to explore the relationship between low treatment adherence and neuropsychological functioning of bipolar patients with a particular focus on the effect of age. We hypothesized that low treatment adherence would be associated with worse neuropsychological functioning in older patients.

## Materials and methods

### Study design and sample

We conducted a cross-sectional multicenter study involving the 9 French Expert Centers of the FondaMental foundation. We used data extracted from the FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) cohort [28]. Among the 1368 outpatients evaluated in the French FACE-BD from January 2009 to January 2015, we included 353 patients in this study diagnosed with BD (type I, II or Not Otherwise Specified (NOS)) according to the selection procedure described in Fig 1. Because of the worsening of cognitive impairment in patients with BD during the acute phase [1], only patients without a current mood episode for at least 3 months, according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., revised (DSM-IV-TR) criteria [29] were included. Patients were included if they were in remission in accordance with the definition proposed by ISBD task force [30]; that is patients who scored <12 on the Montgomery-Asberg Depression Rating Scale (MADRS) [31] and <8 on the Young Mania Rating Scale (YMRS) [32] to avoid the confounding effects of mood symptoms. Since our aim was to clarify the relationship between neuropsychological functioning and medication adherence, we excluded patients without current specific pharmacological treatment. Patients with a history of neurological disease and patients who had received electroconvulsive therapy within 12 months were also excluded from the sample. As reported in previous studies, these two factors could affect neuropsychological functioning [33–36].

The assessment protocol was approved by the ethical review board (CPP-Ile de France IX, January, 18th; 2010). The ethical board requested that each patient receive an information letter. In this case, although written formal consent was not required, seeking permission from



**Fig 1. Selection procedure.** Selection procedure of the final sample of bipolar outpatients (N = 353) from the FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) cohort.

<https://doi.org/10.1371/journal.pone.0184313.g001>

patients was a prerequisite to any analysis of the clinical data. A web-based application was developed to collate assessment data for clinical monitoring and research purposes. Access to the system was carefully regulated, and approval was obtained from the committee in charge of the safety of computerized databases (CNIL; DR-2011-069).

### Clinical assessment

The Structured Clinical Interview for DSM-IV-TR APA/2000 (SCID-I) [37] was used to determine diagnosis of BD I, II or NOS and all psychiatric comorbidities. Demographic and clinical variables were collected from the patient sample, including age, gender, level of education, lifetime psychotic symptoms, lifetime substance use disorder or smoking, lifetime anxiety disorder, number of hospitalizations, illness duration, and number and type of medication. Mood

symptoms were evaluated through the MADRS and YMRS. Anxiety was evaluated by the State-Trait Anxiety Inventory [38]. Side effects were evaluated with the Patient Rated Inventory of Side Effects (PRISE)[39]. Treatment adherence was measured by the Medication Adherence Rating Scale (MARS) [40]. This scale consisted of a self-reporting instrument with 10 yes/no items (i.e. “Do you ever forget to take your medication?” or “It is unnatural for my mind and body to be controlled by medication”) [40–42]. The total score is obtained by summing the items. Patients with a score  $< 8$  were categorized as *low adherent* since the low score was correlated with a low likelihood of medication adherence [40, 43] and patients with a total score  $\geq 8$  were qualified as *high adherent* since it was associated with a high likelihood of medication adherence [40, 43].

## Neuropsychological assessment

Trained professionals administered a 3-hour standardized cognitive battery that included some subtests of the Wechsler Adult Intelligence Scale (WAIS) [44, 45] and other neuropsychological tests. In fact, the neuropsychological tests and subtests used in our study are part of the BANC (Battery for Assessment of Neurocognition) established by the International Society for Bipolar Disorders in order to study cognitive impairments in bipolar disorder patients [46]. Because a new version of the battery (WAIS IV) was launched during the inclusion period, we used the percent of correct responses when the total number of items differed between the 2 versions. The neuropsychological battery assessed 5 cognitive domains:

- Intellectual functioning was assessed with percent of correct responses on the Vocabulary Subtest (asking the meaning of words) and the raw score on the Matrix Reasoning Subtest (logical reasoning on abstract material) of the WAIS-III-R or IV.
- Processing speed was measured with raw scores on the Symbol subtest (crossing out as quickly as possible target symbols within a set of symbols over a 120 second time period) and percent of correct responses on the Coding subtest (writing down as quickly as possible the symbol corresponding to the digit following a digit-symbol code over a 120 second period) of the WAIS-III-R or IV.
- Verbal learning and memory were evaluated with the California Verbal Learning Test (CVLT)[47]. The CVLT is a 5 trial shopping-list learning test with immediate and delayed recalls, both free and semantically cued. The list consists of 16 words: 4 items from 4 semantically distinct categories. The CVLT also includes a final recognition task. The CVLT structure is well suited not only to study consolidation deficits but also to test acquisition difficulties. We selected one outcome measure from the CVLT, which included total learning trials 1 to 5, free delayed recall and recognition.
- Working Memory was evaluated with the percent of correct responses of the WAIS-III-R or IV Digit Span subtest in which the patients had to repeat a series of digits in correct and reverse order.
- Executive functions were assessed by 3 tests. Firstly, the Trail Making Test (TMT) [48] which also evaluates processing speed [49–51], and consists of 2 parts (A and B) that must be performed as quickly and accurately as possible. TMT-A requires subjects to draw lines sequentially to connect in ascending order, the 25 encircled numbers randomly distributed on a sheet of paper (i.e., 1–2–3–4, etc.). In TMT-B, the subject must alternate between numbers (1–13) and letters (A–L) while connecting them with lines (i.e., 1–A–2–B–3–C, etc.). TMT B-A completion time is usually used as an index of executive function since it reflects



the ability for cognitive alternation and processing speed [52, 53]. Secondly, we used the Verbal Fluency Test which evaluates both verbal ability and executive control [54]. In this test, participants needed to retrieve words, which required them to access their mental lexicon. We used Semantic Fluency (the total number of animals named in 120 seconds) and Phonemic Fluency (the total number of words beginning with the letter “P” named in 120 seconds). Third, we used the Stroop Color-Word Interference Test (SCWT) [55]. This is believed to provide a measure of cognitive inhibition or the ability to inhibit an overlearned task (i.e., dominant response) in favor of an unusual one [56]. In this test, participants are required to read as many items as they can in 45 seconds from a card with 100 black-color words (W), a card with 100 colored XXXXs (C), and a card with 100 incongruent color words (WC). The outcome variables are the number of items completed for the word card (W: raw word score), the color card (C: raw color score), and the color–word card (CW: raw color–word score), respectively. We chose the Stroop Interference Score because it measures a cognitive form of inhibition known as interference control [57] so that a low score indicates poor inhibition performances. Interference scores are based on the following equation from the manual:  $CW \text{ raw score} - [(W \text{ raw score} \times C \text{ raw score}) / (W \text{ raw score} + C \text{ raw score})]$ .

## Statistical analyses

Data are expressed as proportions and frequency for categorical variables or means and standard deviations for continuous variables. Normality was assessed with the Shapiro-Wilk test. It has been suggested by the literature that age may be a major confounding factor of the association between adherence and neuropsychological functioning as it influences both dimensions. In order to investigate the specific effect of age, the 353 patients included were split into 2 age-groups based on the second tertile as 16–46 and 47–71 years. So as to verify that the 2 age-groups of patients (16–46 and 47–71 years) were comparable in terms of clinical, socio-demographic and neuropsychological characteristics, univariate analyses were performed. For continuous variables, the comparisons were made with Student tests or Mann-Whitney tests depending on the distribution of the variables while categorical variables were compared across the 2 groups using Chi-square tests. Univariate logistic regression analyses with adherence status according to the MARS score as the dependent variable (categorized as high or low adherent) were performed in both young and old bipolar patients groups separately in order to select the relevant clinical and neuropsychological predictors of nonadherence in both age’s groups. The selection of the predicting variables included in the regression models was based on a threshold of  $p < 0.20$  in the univariate analysis. Then, stepwise multiple logistic regression analyses were conducted in both the young and the old groups separately with adherence status according to the MARS score as the dependent variable (categorized as high or low adherent) and the age specific predictors highlighted in each group as the independent variables. As we included neuropsychological raw scores in the model, we also included usual confounding variables in neuropsychological analysis such as education level, age and gender. Multicollinearity was examined by evaluating the Variance Inflation Factors (VIF) of the selected predictors when running the models in the 2 groups of patients. No multicollinearity issues were identified (with all VIF values  $< 2$ ). The threshold for statistical significance was defined to  $p < 0.05$ . Data were analyzed using the Statistical Package of the Social Sciences (SPSS), version 20 (IBM Corporation, Armonk, NY, USA).

## Results

A total of 353 euthymic patients with BD from the FACE-BD cohort were enrolled in this study. The clinical, socio-demographic, and other characteristics of the patients are provided in [Table 1](#). Most participants were females (61.8%) and the mean age of participants was 40.7 (SD = 12.7). The majority of the patients had obtained a graduate level diploma (37.1%). Patients were diagnosed with BD I (57.8%), with BD II (31.7%), or with BD NOS (10.5%).

The univariate comparisons across the young and old bipolar patients subgroups showed that the 2 groups were comparable on numerous characteristics such as the gender repartition, the education level, the adherence status according to the MARS score, lifetime hospitalizations, the presence of residual symptoms (MADRS and YMRS scores), the level of adverse effects (PRISE-M score) and trait anxiety (STAI-Ya score), lifetime smoking status, medications except for the use of antidepressants, performances at verbal fluencies, SCWT and forward digit span (see [Table 1](#) for more details). But there were also few statistically significant differences between the 2 age-groups, especially regarding neuropsychological performances, with the young patients performing better than their elders (see [Table 1](#) for more details).

Before performing multiple stepwise logistic regression analyses, univariate logistic regressions of all the potential clinical, socio-demographic and neuropsychological predictors on the adherence category (low vs high) were conducted separately in the 2 age groups. In the young patients group, age, illness duration, number of hospitalizations, adverse effects, depressive residual symptoms and state anxiety score, history of lifetime substance abuse, current lithium medication and the SCWT interference score were the most associated factors to low adherence ([Table 2](#)). Whereas in the older group, the predictors retained to explain the adherence category were the illness duration, the number of hospitalizations, the adverse effects score, the history of lifetime smoking, the use of typical antipsychotics, the phonemic verbal fluency raw score and the SCWT interference score ([Table 2](#)).

The previous selected age specific predictors were entered in 2 separate multiple stepwise logistic regression analyses to explain low adherence. Age, gender and education category were also included in the regressions models as potential confounding variables. [Table 3](#) presents the initial and final steps of the analysis. In the younger patients, the analyses reveal that the most associated factors to low adherence were a smaller number of hospitalizations ( $OR = 0.846, p = 0.012$ ), a shorter illness duration ( $OR = 0.937, p = 0.003$ ) and higher adverse effects ( $OR = 1.082; p = 4.457e-4$ ). In the oldest patients, the factors retained to explain adherence were again a smaller number of hospitalizations ( $OR = 0.727, p = 0.008$ ) and higher adverse effects ( $OR = 1.124, p = 0.005$ ) but also poor inhibition performances evaluated by the SCWT interference score ( $OR = 0.924, p = 0.030$ ).

Antidepressant medication was not equally distributed within our sample which could influence medication adherence due to the side effects or potential neuroprotective effects of antidepressants. Therefore, the use of antidepressants could constitute a hidden confounding effect and the effect of antidepressant medication has been tested and the variable was forced in both backward logistic regression models. Of note, our main result was unchanged as inhibition performances were still a significant predictor of low adherence only in the older patients ( $OR = 0.923 [0.855-0.998], p = 0.044$ ).

## Discussion

This is the first cross-sectional study investigating the link between neurocognition and low treatment adherence in BD with a particular focus on the effect of age. Interestingly, our result suggests that the association between adherence and executive functioning varies as a function of age. More precisely, we demonstrated that in older euthymic bipolar patients,



**Table 1. Socio-demographic and clinical description of the sample by age groups.**

	Whole Sample (N = 353)	Age category		Statistics	p-value
		Young (N = 241)	Old (N = 112)		
<i>Sociodemographic characteristics</i>					
Age Mean (SD)	40.67 (12.66)	33.77 (8.07)	55.54 (6.39)	-	-
Sex (Male/Female) N (%)	135/218 (38.2/61.8)	86/155 (35.7/64.3)	49/63 (43.8/56.2)	Chi-square	0.147
Education category N (%)					
High school diploma incomplete	51 (14.4)	34 (14.1)	17 (15.2)	Chi-square	0.824
High school diploma obtained	51 (14.4)	37 (15.4)	14 (12.5)		
Bachelor incomplete or obtained	120 (34.0)	79 (32.8)	41 (36.6)		
Graduate level diploma obtained	132 (37.1)	91 (37.8)	40 (35.7)		
<i>Clinical variables</i>					
<b>Bipolar Disorder subtype</b>					
BD I N (%)	204 (57.8)	153 (63.5)	51 (45.5)	Chi-square	<b>0.005</b>
BD II N (%)	112 (31.7)	68 (28.2)	44 (39.3)		
BD Nos N (%)	37 (10.5)	20 (8.3)	17 (15.2)		
Adherence group (High /Low) N (%)	186/167 (52.7/47.3)	119/122 (49.4/50.6)	67/45 (59.8/40.2)	Chi-square	0.067
Age at onset Mean (SD)	24.4 (9.1)	21.54 (6.10)	30.52 (11.40)	U Mann-Whitney	<b>&lt;0.001</b>
Illness duration (years) Mean (SD)	16.9 (11.4)	12.83 (8.08)	26.10 (12.47)	U Mann-Whitney	<b>&lt;0.001</b>
Number of hospitalizations Mean (SD)	2.9 (2.7)	2.78 (2.72)	3.03 (2.79)	U Mann-Whitney	0.448
Lifetime psychotic symptoms N (%)	155 (53.4)	123 (60.0)	32 (37.6)	Chi-square	<b>0.001</b>
MADRS score Mean (SD)	4.1 (3.4)	4.14 (3.38)	3.95 (3.49)	U Mann-Whitney	0.514
YMRS score Mean (SD)	1 (1.6)	0.95 (1.59)	1.04 (1.53)	U Mann-Whitney	0.384
PRISE-M score Mean (SD)	10.3 (8.1)	10.71 (8.04)	9.55 (8.17)	U Mann-Whitney	0.123
STAI Y-A score Mean (SD)	36.3 (12.8)	36.75 (12.70)	35.23 (13.09)	U Mann-Whitney	0.156
<i>Comorbidities</i>					
Lifetime Anxiety disorder N (%)	76 (23.0)	61 (26.5)	15 (14.9)	Chi-square	<b>0.020</b>
Lifetime Substance Use disorder N (%)	87 (26.1)	68 (29.7)	19 (18.3)	Chi-square	<b>0.028</b>
Lifetime Smoking N (%)	174 (54.9)	124 (56.6)	50 (51.0)	Chi-square	0.354
<i>Treatment</i>					
Number of Medication Mean (SD)	1.8 (0.8)	1.76 (0.78)	1.82 (0.81)	U Mann-Whitney	0.565
Lithium N (%)	118 (33.4)	77 (32.0)	41 (36.6)	Chi-square	0.388
Anticonvulsants N (%)	187 (53)	129 (53.5)	58 (51.8)	Chi-square	0.760
Antidepressants N (%)	149 (42.2)	92 (38.2)	57 (50.9)	Chi-square	<b>0.024</b>
Typical Antipsychotics N (%)	26 (7.4)	18 (7.5)	8 (7.1)	Chi-square	0.913
Atypical Antipsychotics N (%)	136 (38.5)	101 (41.9)	35 (31.2)	Chi-square	0.055
<i>Neuropsychological variables Mean (SD)</i>					
WAIS Symbols raw score	32.93 (8.05)	34.80 (7.78)	28.83 (7.07)	U Mann-Whitney	<b>&lt;0.001</b>
WAIS Coding Percent correct	50.10 (11.77)	52.94 (11.01)	43.83 (10.97)	U Mann-Whitney	<b>&lt;0.001</b>
Trail Making Test B—A Time (s)	47.32 (36.95)	41.82 (27.75)	59.17 (49.56)	U Mann-Whitney	<b>0.001</b>
CVLT List a Total 1–5 raw score	56.60 (11.37)	58.11 (10.63)	53.39 (12.26)	U Mann-Whitney	<b>0.003</b>
CVLT Recognition raw score	15.04 (1.39)	15.23 (1.12)	14.64 (1.78)	U Mann-Whitney	<b>0.002</b>
CVLT Free Delayed Recall raw score	12.27 (3.15)	12.76 (2.79)	11.22 (3.60)	U Mann-Whitney	<b>&lt;0.001</b>
WAIS Forward Digit Span Percent correct	56.91 (12.19)	57.70 (12.44)	55.23 (11.53)	U Mann-Whitney	0.109
WAIS Backward Digit Span Percent correct	45.56 (14.07)	47.71 (14.44)	41.02 (12.12)	U Mann-Whitney	<b>&lt;0.001</b>
Phonemic Verbal Fluency raw score	22.60 (6.51)	22.76 (6.28)	22.23 (7.01)	U Mann-Whitney	0.505
Semantic Verbal Fluency raw score	30.66 (7.28)	30.81 (7.39)	30.33 (7.07)	U Mann-Whitney	0.747

(Continued)

Table 1. (Continued)

	Whole Sample (N = 353)	Age category		Statistics	p-value
		Young (N = 241)	Old (N = 112)		
SCWT Interference score	1.07 (7.90)	1.19 (8.18)	0.83 (7.30)	U Mann-Whitney	0.687

Abbreviations: CVLT, California Verbal Learning Test; MADRS, Montgomery Asberg Depression Rating Scale; NOS, not otherwise specified; PRISE-M, Patient Rated Inventory of Side Effects; SCWT, Stroop Color and Word Test; STAI-Y-a, State Trait Anxiety Inventory Y form assessing State Anxiety; WAIS, Wechsler Adult Intelligence Scale; YMRS, Young Mania Rating Scale.

<https://doi.org/10.1371/journal.pone.0184313.t001>

poor inhibition performances predict low adherence while no significant effect was found in younger patients. In addition to this new finding, our study replicates the well-studied effect of the amount of adverse effects on adherence [5, 6] that experiencing a high level of adverse effects is a risk factor for low adherence but we proved that this effect has to be considered whatever the age of the patient. We also demonstrate that a small number of lifetime hospitalizations predicts low-adherence regardless of age. It suggests that greater number of hospitalizations can lead to better adherence which supports the hypothesis of a learning effect from these episodes and is consistent with previous observations indicating that having experienced fewer episodes is a risk factor for low-adherence in bipolar disorder patients [11]. Besides, this learning effect is also in line with our last result indicating that a short illness duration constitutes a risk factor for low-adherence but in young bipolar patients only.

Our main finding is consistent with several studies that demonstrated a decline in executive functioning with aging [23, 58], and another study which showed an age by disease interaction, with older patients with BD performing most poorly [59]. Moreover, our results are in accordance with some previous studies focusing on the relationship between adherence and neurocognition. Martinez-Aran et al investigated whether low treatment adherence is associated with cognitive impairment in 103 euthymic patients with BD [19]. They showed that patients with low adherence have significantly poorer performance on several cognitive functions. First, they were more impaired in the verbal learning and cued short recall tasks of CVLT than the other groups (i.e., high compliance and control), and furthermore, the Stroop Interference Score was lower in low adherent patients compared to controls. Finally, they demonstrated that TMT-B, which can also be considered as a measure of executive functioning, was significantly lower compared with both groups. However, after controlling for the confounding effect of several variables, only the TMT-B performance remained significant. These results also support an implication of executive processing in treatment adherence in BD even if the involved neuropsychological test was different. These differences might be explained by methodological differences and more restrictive inclusion criteria, that is, patients with less residual symptoms and without substance use disorder. Similarly, a study including 120 patients with BD with current depressed or mixed episode and cocaine dependence, found that baseline cognitive functioning measured by the Stroop Color-Word test and performance in simple visual attention tasks, assessed by the Stroop Word condition, was inversely associated with treatment adherence [20]. By contrast, another study [22] found no difference in neurocognitive performance according to adherence in a sample of 101 patients with BD, who were mostly euthymic, and 154 patients with a schizophrenia spectrum disorder. It is worth noting that these previous studies show conflicting results that might be explained by a limited sample size, the inclusion of non-euthymic patients vs. strictly euthymic patients or a confounding age effect.

Associations between unintentional adherence and neurocognitive function have been previously described in different medical conditions such as in hypertension, systematic lupus erythematosus, dementia and late-life depression [18, 60–62]. Even if the MARS was not

**Table 2. Univariate logistic regressions to predict low adherence (versus high adherence) in young (16–46 years) and old (47–71 years) bipolar patients' subgroups.**

	Age Bipolar patients' subgroups			
	Young (N = 241)		Old (N = 112)	
	OR	p	OR	p
<i>Sociodemographics and clinical variables</i>				
Age	0.958	0.009	1.011	0.719
Sex—Female	1.117	0.680	0.954	0.903
Education—High school diploma incomplete	0.832	0.648	0.625	0.450
Education—High school diploma obtained	0.638	0.256	2.000	0.271
Education—Bachelor incomplete or obtained	1.177	0.598	0.960	0.928
Education—Graduate level diploma obtained	-	0.474	-	0.486
Bipolar Disorder subtype—BD I	0.851	0.735	0.922	0.886
Bipolar Disorder subtype—BD II	0.771	0.611	0.989	0.985
Bipolar Disorder subtype—BD Nos	-	0.869	-	0.982
Age at onset	0.987	0.548	1.020	0.256
Illness duration	0.944	0.003	0.977	0.175
Number of hospitalizations	0.829	0.002	0.826	0.027
Lifetime psychotic symptoms	1.363	0.279	0.633	0.324
MADRS score	1.139	0.001	1.055	0.336
YMRS score	0.965	0.660	1.022	0.860
PRISE-M score	1.078	<0.001	1.110	0.001
STAI Y-A score	1.023	0.032	1.018	0.231
Lifetime Anxiety disorder	0.839	0.556	0.747	0.605
Lifetime Substance Use disorder	0.589	0.071	0.671	0.435
Lifetime Smoking	1.319	0.311	0.560	0.163
Number of Medications	0.844	0.309	1.189	0.468
Lithium	0.632	0.100	0.927	0.850
Anticonvulsants	0.917	0.736	1.288	0.513
Antidepressants	0.895	0.677	1.589	0.233
Typical Antipsychotics	0.765	0.587	2.667	0.195
Atypical Antipsychotics	1.303	0.312	0.580	0.205
<i>Neuropsychological variables</i>				
WAIS Symbols raw score	1.017	0.308	0.974	0.350
WAIS Coding Percent correct	1.007	0.538	1.002	0.913
Trail Making Test B—A (Time)	1.005	0.350	1.000	0.914
CVLT List a Total 1–5 raw score	1.003	0.783	0.995	0.772
CVLT Recognition raw score	0.893	0.338	1.021	0.848
CVLT Free Delayed Recall raw score	1.004	0.921	1.007	0.896
WAIS Forward Digit Span Percent correct	1.001	0.907	0.995	0.767
WAIS Backward Digit Span Percent correct	0.998	0.862	0.991	0.589
Phonemic Verbal Fluency raw score	1.003	0.893	1.040	0.181
Semantic Verbal Fluency raw score	1.021	0.250	0.993	0.802
SCWT Interference score	1.037	0.030	0.934	0.020

Abbreviations: CVLT, California Verbal Learning Test; MADRS, Montgomery Asberg Depression Rating Scale; PRISE-M, Patient Rated Inventory of Side Effects; SCWT, Stroop Color and Word Test; STAI-Y-a, State Trait Anxiety Inventory Y form assessing State Anxiety; WAIS, Wechsler Adult Intelligence Scale; YMRS, Young Mania Rating Scale.

<https://doi.org/10.1371/journal.pone.0184313.t002>

**Table 3. Separate multiple logistic regressions to predict low adherence (versus high adherence) in young (16–46 years) and old (47–71 years) bipolar patients' subgroups before and after backward selection procedures.**

Factors	$\beta$	<i>p</i>	Adjusted Odds Ratio	95% Confidence Interval
<b>Young (n = 241)</b>				
<i>Step 1<sup>a</sup></i>				
Age	-0.022	0.434	0.979	0.927–1.033
Sex	-0.200	0.585	0.819	0.399–1.679
Education—High school diploma incomplete	-0.726	0.168	0.484	0.172–1.358
Education—High school diploma obtained	-0.875	0.102	0.417	0.146–1.188
Education—Bachelor incomplete or obtained	0.048	0.905	1.049	0.475–2.315
Education—Graduate level diploma obtained	-	0.198	-	-
Number of Hospitalizations	-0.185	0.011	0.831	0.720–0.959
Illness Duration	-0.043	0.149	0.958	0.903–1.016
PRISE-M score	0.067	0.022	1.069	1.010–1.132
Lithium medication	0.408	0.252	1.504	0.748–3.022
Lifetime Substance Use disorder	0.314	0.412	1.369	0.647–2.895
MADRS score	0.035	0.569	1.036	0.917–1.170
STAI Y-A score	0.014	0.385	1.014	0.982–1.047
SCWT Interference score	0.032	0.120	1.032	0.992–1.074
<i>Final Step</i>				
<b>Number of Hospitalizations</b>	-0.168	0.012	0.846	0.742–0.964
<b>Illness Duration</b>	-0.065	0.003	0.937	0.899–0.979
<b>PRISE-M score</b>	0.079	<0.001	1.082	1.035–1.131
<b>Old (n = 112)</b>				
<i>Step 1<sup>a</sup></i>				
Age	0.005	0.922	1.005	0.909–1.112
Sex	-0.073	0.907	0.930	0.276–3.138
Education—High school diploma incomplete	0.435	0.664	1.546	0.217–11.012
Education—High school diploma obtained	0.688	0.475	1.989	0.302–13.117
Education—Bachelor incomplete or obtained	0.614	0.385	1.847	0.436–7.375
Education—Graduate level diploma obtained	-	0.826	-	-
Number of Hospitalizations	-0.257	0.057	0.773	0.594–1.007
Illness Duration	-0.049	0.065	0.952	0.903–1.003
PRISE-M score	0.143	0.003	1.153	1.049–1.268
Typical Antipsychotics	-0.704	0.581	0.495	0.041–6.041
Lifetime Smoking	1.059	0.083	2.884	0.869–9.568
Semantic Verbal Fluency Raw score	0.074	0.137	1.076	0.977–1.186
SCWT Interference score	-0.086	0.044	0.917	0.843–0.998
<i>Final Step</i>				
<b>Number of Hospitalizations</b>	-0.319	0.008	0.727	0.574–0.921
<b>PRISE-M score</b>	0.117	0.005	1.124	1.035–1.220
<b>SCWT Interference score</b>	-0.079	0.030	0.924	0.861–0.992

<sup>a</sup>The variables included in steps 1 are the variables with a *p*<0.20 in the univariate regression analyses (see Table 2).

Abbreviations: MADRS, Montgomery Asberg Depression Rating Scale; PRISE-M, Patient Rated Inventory of Side Effects; STAI-Y-a, State Trait Anxiety Inventory Y form assessing State Anxiety; SCWT, Stroop Color and Word Test.

<https://doi.org/10.1371/journal.pone.0184313.t003>

originally designed to assess intentionality of adherence behavior, some authors have highlighted that the 2 first items of the MARS are an appropriate measure of unintentional non-adherence (i.e. “Do you ever forget to take your medication?”, “Are you careless at times about taking your medicine?”) while the others 8 items evaluate intentional non-adherence

[63]. Based on these results, from an exploratory approach, we created two dimensions from the MARS' items: intentional (sum of items 3–8) and unintentional (sum of items 1 & 2). Interestingly, in the older bipolar patients, the SCWT interference score was positively correlated with only the unintentional dimension of non-adherence ( $r = 0.26$ ,  $p = 0.006$ ).

To the best of our knowledge, only one previous study that included patients with HIV infection examined the hypothesis of an age effect in the relationship between neurocognition and medication adherence [27]. A sample of 431 HIV-infected adults was divided into two groups: younger (age < 50 years) and older. In this study, neurocognitive impairment was associated with poorer medication adherence among older participants only. When cognitive subdomains were examined individually, executive functioning, motor functioning, and processing speed were most strongly related to adherence in this age group. These results are in accordance with our findings.

Thus, our results emphasize the relevance of considering age in the relationship between adherence and neuropsychological performances, and underline the importance of executive functioning in adherence behavior in older patients. In psychiatric disorders, our study is the first to show this interaction between age and executive processing when focusing on poor adherence to treatment.

Two different plausible explanations that can be concurrent and may influence each other could be hypothesized to account for the association between cognitive functioning and adherence. One could consider that low adherence might be a consequence of poor executive functioning in older patients. Prospective memory, which is the “memory for activities to be performed in the future” [64], involves executive functioning such as cognitive flexibility and planning, which is assumed by the recruitment of the prefrontal cortex during prospective memory tasks [65–67]. Interestingly, deficits in prospective memory have been related to medication nonadherence in different clinical populations [67]. Furthermore, prospective memory has been shown to be lower in patients with BD even in remission phases [68, 69] and to decline with aging in the general population [70, 71]. Age-related executive impairments are also postulated to be associated with a deterioration of the frontal lobe [72, 73], and in BD further evidence of abnormal prefrontal cortical activity in remitted patients during performance of the Stroop task has been shown [74–76]. Therefore, we can hypothesize that a decline of executive functioning could lead to impairment in prospective memory and therefore an increased risk for medication nonadherence in older patients with BD.

An alternative explanation could account for the link between adherence and cognition. This posits that low adherence in BD may be a cause of poor executive functioning in older patients. Low adherence to medication leads to more relapses and recurrences of disease [7, 8], which cause impairment in cognitive functioning [77, 78]. It is reasonable to assume that older patients with BD are those who have accumulated the highest number of episodes and therefore have a greater risk of showing cognitive impairment. However, in our study, we have statistically controlled the analysis for the number of hospitalizations and the duration of illness which allows us to conclude that these variables have an independent effect on adherence. Consequently, the first hypothesis seems to be more plausible in the context of our study.

When extrapolating to clinical practice, our results suggest that targeted cognitive remediation programs might be proposed in addition to classic psychoeducative programs to improve medication adherence. Together, these approaches may enhance executive functioning, especially inhibition skills, in remitted patients over 47 years old with BD. A recent meta-analysis indicated that cognitive remediation in BD seemed to have promising results, but further studies are needed to evaluate the efficacy of interventions combining cognitive remediation and biological treatments [79].

The current study has several limitations. First, the use of a cross-sectional design and the absence of a healthy control group to control for the effect of natural aging require further longitudinal studies investigating the course of cognitive functioning and treatment adherence in regard to age. We suggest that it is important to clarify how aging, adherence, and neuropsychological functioning interact in the context of BD because current studies do not allow us to determine the mechanisms behind this observed association. Second, another methodological issue of our work is the definition of our low and good adherent groups and the categorization of age. However, the cut-off used for the MARS,  $\geq 8$ , is the one recommended in previous studies [40, 43] and also corresponds to the median score of our sample (median score = 8; Inter-quartile range [6–9]). In fact, two post-hoc analyses have been conducted either adjusting the cut-off score to 6 or categorizing adherence into 3 groups in order to prevent a possible categorization induced bias. The effect of the SCWT interference score was replicated when considering a cut-off score of 6 (OR = 0.910 [0.843–0.982],  $p = 0.016$ ) as well as when using 3 categories of adherence levels (OR = 0.877 [0.777–0.990],  $p = 0.033$ ). Concerning the categorization of age in our sample, patients aged under the second tertile have been categorized as young (16–46 years) whereas patients aged over the second tertile have been categorized as old (47–71 years). This arbitrary categorical approach provides the advantage of facilitating the interpretation of the regression results. Accordingly, Johnson et al [80] described a quadratic influence of age on treatment adherence with a decrease up to 41 years and an increase beyond 41, which advocates for a binary categorization of age when studying adherence in BD. Third, some selection bias could be highlighted and moderates the generalization of our findings, such as the constrained criteria for euthymia and recruitment in tertiary specialized centers. It can be assumed that euthymic patients with few residual symptoms, who are followed in a Center of Expertise for BD represent a smaller specific category of BD patients who are probably more adherent. Moreover, this sample of bipolar patients were highly educated with about 2/3 having post-secondary education. Another limit of our study concerns the use of the stepwise backward selection procedure, in our logistic regressions analyses, that is known to inflate the Type I error rates (i.e., probability of erroneously rejecting a true null-hypothesis) due to multiple testing issues [81]. To limit this bias, the initial analyses were re-conducted with the ENTER method (variables selected if relevant according to the literature or if  $p < 0.10$  in univariate analyses). These new analyses produced comparable results, indicating that inhibition performances are significant predictors of low adherence only in older bipolar patients.

Finally, our study has several strengths. We selected the largest sample in comparison with previous studies cited above. We used strict euthymia as inclusion criteria. The neurocognitive battery used a wide range of measures which encompassed cognitive function impaired in BD and selected tests according to the International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC) [46]. In addition, our protocol took into account a large set of potentially confounding variables and the resulting models lead to the correct classification of 67.5% of the young patients and 71.7% of the old patients as low or high adherent.

## Conclusions

In conclusion, our data suggest that adherence is associated to executive functioning in older patients only. In bipolar disorder, the impact of cognitive functioning on adherence may depend on age. It highlights the necessity of considering age in further studies and creating age-adapted therapeutic interventions to improve medication adherence.



## Acknowledgments

The authors thank the FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) collaborators: FACE-BD lead author: C. Henry ([chantal.henry@inserm.fr](mailto:chantal.henry@inserm.fr)); FACE-BD clinical coordinating centers: M. Leboyer, B. Etain; FACE-BD data coordinating centers: H. Laouamri, K. Souyris; FACE-BD clinical sites and principal collaborators in France: AP-HP, Henri Mondor—Albert Chenevier Hospitals, psychiatric pole, Créteil: J-P. Sanchez, AP-HP, Saint-Louis—Lariboisière Fernand—Widal Hospital, neuroscience pole, Paris: S. Sportiche, C. Lecornu, Charles Perrens Hospital, Bordeaux: B. Antonioli, A. Desage, Department of psychiatric emergency and post-emergencies, Lapeyronie academic Hospital, Montpellier: F. Molière, D. Ducasse, Psychiatric department, Sainte-Marguerite Hospital, Marseille: J. Montant, M-A. Lodovighi, N. Viglianesi, O. Perret, L. Lescalier, Department of psychiatry and clinical psychology, Psychotherapeutic Centre of Nancy, Laxou: R. Cohen, Department of Psychiatry, Academic Hospital of Grenoble, Grenoble: S. Garçon, Psychiatric ward, Academic Hospital of Versailles, Le Chesnay: C. Passerieux, M.C. Hardy-Bayle, N. Kayser, A-S. Cannavo, Princesse-Grace Hospital, Monaco: V. Aubin, L. Albertini, I. Cussac, E. Beetz.

## Author Contributions

**Conceptualization:** Nadia Corréard, Julia-Lou Consoloni, Jean-Michel Azorin, Raoul Belzeaux.

**Formal analysis:** Nadia Corréard, Julia-Lou Consoloni.

**Funding acquisition:** Marion Leboyer.

**Investigation:** Nadia Corréard, Julia-Lou Consoloni, Aurélie Raust, Bruno Etain, Romain Guillot, Sophie Job, Joséphine Loftus, Isabelle Médecin, Thierry Bougerol, Mircea Polosan, Benjamin Fredembach, Sébastien Gard, Katia M'Bailara, Jean-Pierre Kahn, Paul Roux, Anne-Sophie Homassel, Mathilde Carminati, Lucile Matos, Emilie Olié, Frank Bellivier, Philippe Courtet, Chantal Henry, Marion Leboyer, Jean-Michel Azorin, Raoul Belzeaux.

**Methodology:** Nadia Corréard, Julia-Lou Consoloni, Bruno Etain, Philippe Courtet, Jean-Michel Azorin, Raoul Belzeaux.

**Project administration:** Jean-Michel Azorin.

**Supervision:** Chantal Henry, Marion Leboyer.

**Visualization:** Nadia Corréard, Julia-Lou Consoloni.

**Writing – original draft:** Nadia Corréard, Julia-Lou Consoloni.

**Writing – review & editing:** Aurélie Raust, Bruno Etain, Romain Guillot, Sophie Job, Joséphine Loftus, Isabelle Médecin, Thierry Bougerol, Mircea Polosan, Benjamin Fredembach, Sébastien Gard, Katia M'Bailara, Jean-Pierre Kahn, Paul Roux, Anne-Sophie Homassel, Mathilde Carminati, Lucile Matos, Emilie Olié, Philippe Courtet, Chantal Henry, Marion Leboyer, Jean-Michel Azorin, Raoul Belzeaux.

## References

1. Porter RJ, Robinson LJ, Malhi GS, Gallagher P. The neurocognitive profile of mood disorders—a review of the evidence and methodological issues. *Bipolar Disord.* 2015; 17 Suppl 2: 21–40. <https://doi.org/10.1111/bdi.12342> PMID: 26688288
2. Burdick KE, Russo M, Frangou S, Mahon K, Braga RJ, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. *Psychol Med.* 2014; 44(14): 3083–96. <https://doi.org/10.1017/S0033291714000439> PMID: 25065409

3. Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. *Schizophr Bull.* 2009; 35(5): 1022–9. <https://doi.org/10.1093/schbul/sbn044> PMID: 18495643
4. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. *J Psychopharmacol.* 2016; 30(6): 495–553. <https://doi.org/10.1177/0269881116636545> PMID: 26979387
5. Levin JB, Krivenko A, Howland M, Schlachet R, Sajatovic M. Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review. *CNS Drugs.* 2016; 30(9): 819–35. <https://doi.org/10.1007/s40263-016-0368-x> PMID: 27435356
6. Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. *J Affect Disord.* 2013; 149(1–3): 247–52. <https://doi.org/10.1016/j.jad.2013.01.036> PMID: 23489403
7. Goodwin FK, Jamison KR, Ghaemi SN. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York, N.Y.: Oxford University Press; 2007. xxvi, 1262 p. p.
8. Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. *Psychiatry Res.* 2011; 190(1): 110–4. <https://doi.org/10.1016/j.psychres.2011.04.016> PMID: 21571375
9. Belzeaux R, Correard N, Boyer L, Etain B, Loftus J, Bellivier F, et al. Depressive residual symptoms are associated with lower adherence to medication in bipolar patients without substance use disorder: results from the FACE-BD cohort. *J Affect Disord.* 2013; 151(3): 1009–15. <https://doi.org/10.1016/j.jad.2013.08.028> PMID: 24051101
10. Perlis RH, Ostacher MJ, Miklowitz DJ, Hay A, Nierenberg AA, Thase ME, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. *J Clin Psychiatry.* 2010; 71(3): 296–303. <https://doi.org/10.4088/JCP.09m05514yel> PMID: 20331931
11. Lingam R, Scott J. Treatment non-adherence in affective disorders. *Acta Psychiatr Scand.* 2002; 105(3): 164–72. PMID: 11939969
12. Sajatovic M, Blow FC, Kales HC, Valenstein M, Ganoczy D, Ignacio RV. Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder. *Int J Geriatr Psychiatry.* 2007; 22(10): 992–8. <https://doi.org/10.1002/gps.1777> PMID: 17323327
13. Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, et al. Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. *J Clin Psychopharmacol.* 2016; 36(4): 355–71. PMID: 27307187
14. Wroe AL. Intentional and unintentional nonadherence: a study of decision making. *J Behav Med.* 2002; 25(4): 355–72. PMID: 12136497
15. Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. *Int J Nurs Stud.* 2007; 44(8): 1468–77. <https://doi.org/10.1016/j.ijnurstu.2006.07.010> PMID: 16973166
16. Thaler NS, Sayegh P, Arentoft A, Thames AD, Castellon SA, Hinkin CH. Increased neurocognitive intra-individual variability is associated with declines in medication adherence in HIV-infected adults. *Neuropsychology.* 2015; 29(6): 919–25. <https://doi.org/10.1037/neu0000191> PMID: 25730729
17. Manning KJ, Clarke C, Lorry A, Weintraub D, Wilkinson JR, Duda JE, et al. Medication management and neuropsychological performance in Parkinson's disease. *Clin Neuropsychol.* 2012; 26(1): 45–58. <https://doi.org/10.1080/13854046.2011.639312> PMID: 22150514
18. Dalebout GM, Broadbent E, McQueen F, Kaptein AA. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. *Arthritis Care Res (Hoboken).* 2011; 63(3): 342–50. <https://doi.org/10.1002/acr.20411> PMID: 21120967
19. Martinez-Aran A, Scott J, Colom F, Torrent C, Tabares-Seisdedos R, Daban C, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. *J Clin Psychiatry.* 2009; 70(7): 1017–23. <https://doi.org/10.4088/JCP.08m04408> PMID: 19497247
20. Fagan CS, Carmody TJ, McClintock SM, Suris A, Nakamura A, Jeon-Slaughter H, et al. The effect of cognitive functioning on treatment attendance and adherence in comorbid bipolar disorder and cocaine dependence. *J Subst Abuse Treat.* 2015; 49: 15–20. <https://doi.org/10.1016/j.jsat.2014.06.008> PMID: 25108685
21. Fuentes I, Rizo-Mendez A, Jarne-Esparcia A. Low compliance to pharmacological treatment is linked to cognitive impairment in euthymic phase of bipolar disorder. *J Affect Disord.* 2016; 195: 215–20. <https://doi.org/10.1016/j.jad.2016.02.005> PMID: 26897294

22. Jonsdottir H, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. *Acta Psychiatr Scand*. 2013; 127(1): 23–33. <https://doi.org/10.1111/j.1600-0447.2012.01911.x> PMID: 22900964
23. Torrent C, Martinez-Aran A, del Mar Bonnin C, Reinares M, Daban C, Sole B, et al. Long-term outcome of cognitive impairment in bipolar disorder. *J Clin Psychiatry*. 2012; 73(7): e899–905. <https://doi.org/10.4088/JCP.11m07471> PMID: 22901360
24. Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. *Psychol Med*. 2011; 41(2): 225–41. <https://doi.org/10.1017/S0033291710001042> PMID: 20836900
25. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. *Clin Geriatr Med*. 2013; 29(4): 737–52. <https://doi.org/10.1016/j.cger.2013.07.002> PMID: 24094294
26. Mann-Wrobel MC, Carreno JT, Dickinson D. Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: an update and investigation of moderator variables. *Bipolar Disord*. 2011; 13(4): 334–42. <https://doi.org/10.1111/j.1399-5618.2011.00935.x> PMID: 21843273
27. Ettenhofer ML, Hinkin CH, Castellon SA, Durvasula R, Ullman J, Lam M, et al. Aging, neurocognition, and medication adherence in HIV infection. *Am J Geriatr Psychiatry*. 2009; 17(4): 281–90. <https://doi.org/10.1097/JGP.0b013e31819431bd> PMID: 19307857
28. Henry C, Etain B, Mathieu F, Raust A, Vibert JF, Scott J, et al. A French network of bipolar expert centres: a model to close the gap between evidence-based medicine and routine practice. *J Affect Disord*. 2011; 131(1–3): 358–63. <https://doi.org/10.1016/j.jad.2010.11.013> PMID: 21144593
29. American Psychiatric Association A. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)*. Arlington, VA: American Psychiatric Association; 2000.
30. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. *Bipolar Disord*. 2009; 11(5): 453–73. <https://doi.org/10.1111/j.1399-5618.2009.00726.x> PMID: 19624385
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry*. 1979; 134: 382–9. PMID: 444788
32. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry*. 1978; 133: 429–35. PMID: 728692
33. Loughman A, Bowden SC, D'Souza W. Cognitive functioning in idiopathic generalised epilepsies: a systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2014; 43: 20–34. <https://doi.org/10.1016/j.neubiorev.2014.02.012> PMID: 24631851
34. Godbolt AK, Cancelliere C, Hincapie CA, Marras C, Boyle E, Kristman VL, et al. Systematic review of the risk of dementia and chronic cognitive impairment after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. *Arch Phys Med Rehabil*. 2014; 95(3 Suppl): S245–56. <https://doi.org/10.1016/j.apmr.2013.06.036> PMID: 24581910
35. Carter JA, Neville BG, Newton CR. Neuro-cognitive impairment following acquired central nervous system infections in childhood: a systematic review. *Brain Res Brain Res Rev*. 2003; 43(1): 57–69. PMID: 14499462
36. Rose D, Fleischmann P, Wykes T, Leese M, Bindman J. Patients' perspectives on electroconvulsive therapy: systematic review. *BMJ*. 2003; 326(7403): 1363. <https://doi.org/10.1136/bmj.326.7403.1363> PMID: 12816822
37. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P)*. New York: New York State Psychiatric Institute, 2002.
38. Spielberger C. *Manual for the State-Trait Anxiety Inventory*. rev. ed. Palo Alto (CA)1983.
39. Bryan C, Songer T, Brooks MM, Rush AJ, Thase ME, Gaynes B, et al. The impact of diabetes on depression treatment outcomes. *Gen Hosp Psychiatry*. 2010; 32(1): 33–41. <https://doi.org/10.1016/j.genhosppsych.2009.07.009> PMID: 20114126
40. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. *Schizophr Res*. 2000; 42(3): 241–7. PMID: 10785582
41. Boyer L, Cermolacce M, Dassa D, Fernandez J, Boucekine M, Richieri R, et al. Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach. *PLoS One*. 2012; 7(10): e47655. <https://doi.org/10.1371/journal.pone.0047655> PMID: 23144705
42. Fialko L, Garety PA, Kuipers E, Dunn G, Bebbington PE, Fowler D, et al. A large-scale validation study of the Medication Adherence Rating Scale (MARS). *Schizophr Res*. 2008; 100(1–3): 53–9. <https://doi.org/10.1016/j.schres.2007.10.029> PMID: 18083007

43. Rosa AR, Marco M, Fachel JM, Kapczynski F, Stein AT, Barros HM. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007; 31(1): 217–24. <https://doi.org/10.1016/j.pnpbp.2006.08.007> PMID: [16982121](https://pubmed.ncbi.nlm.nih.gov/16982121/)
44. Wechsler D. Wechsler Adult Intelligence Scale-Third Edition. (WAIS-III). Paris2000.
45. Wechsler D. Wechsler Adult Intelligence Scale-Fourth Edition. (WAIS-IV). Paris2011.
46. Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). *Bipolar Disord*. 2010; 12(4): 351–63. <https://doi.org/10.1111/j.1399-5618.2010.00830.x> PMID: [20636632](https://pubmed.ncbi.nlm.nih.gov/20636632/)
47. Delis D C K JH, Kaplan E, Ober B A. The California Verbal Learning Test: Research Edition, Adult Version. San Antonio, TX: The Psychological Corporation; 1987.
48. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. *Perceptual and Motor Skills*. 1958; 8: 271–6.
49. Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. *J Clin Exp Neuropsychol*. 2000; 22(4): 518–28. [https://doi.org/10.1076/1380-3395\(200008\)22:4;1-0;FT518](https://doi.org/10.1076/1380-3395(200008)22:4;1-0;FT518) PMID: [10923061](https://pubmed.ncbi.nlm.nih.gov/10923061/)
50. Korte KB, Horner MD, Windham WK. The trail making test, part B: cognitive flexibility or ability to maintain set? *Appl Neuropsychol*. 2002; 9(2): 106–9. [https://doi.org/10.1207/S15324826AN0902\\_5](https://doi.org/10.1207/S15324826AN0902_5) PMID: [12214820](https://pubmed.ncbi.nlm.nih.gov/12214820/)
51. Szoke A, Schurhoff F, Mathieu F, Meary A, Ionescu S, Leboyer M. Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. *Psychol Med*. 2005; 35(6): 771–82. PMID: [15997598](https://pubmed.ncbi.nlm.nih.gov/15997598/)
52. Crowe SF. The differential contribution of mental tracking, cognitive flexibility, visual search, and motor speed to performance on parts A and B of the Trail Making Test. *J Clin Psychol*. 1998; 54(5): 585–91. PMID: [9696108](https://pubmed.ncbi.nlm.nih.gov/9696108/)
53. Loewenstein DA, Ownby R, Schram L, Acevedo A, Rubert M, Arguelles T. An evaluation of the NINCDS-ADRDA neuropsychological criteria for the assessment of Alzheimer's disease: a confirmatory factor analysis of single versus multi-factor models. *J Clin Exp Neuropsychol*. 2001; 23(3): 274–84. <https://doi.org/10.1076/jcen.23.3.274.1191> PMID: [11404806](https://pubmed.ncbi.nlm.nih.gov/11404806/)
54. Cardebat D, Doyon B, Puel M, Goulet P, Joannette Y. [Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level]. *Acta Neurol Belg*. 1990; 90(4): 207–17. PMID: [2124031](https://pubmed.ncbi.nlm.nih.gov/2124031/)
55. Golden CJ. *Diagnosis and rehabilitation in clinical neuropsychology*. Springfield, Illinois: Charles C. Thomas; 1978.
56. Spreen O, Strauss E. *A compendium of neuropsychological tests: Administration, norms, and commentary (2nd Ed.)*. New York: Oxford University Press; 1998.
57. Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. *J Child Psychol Psychiatry*. 1996; 37(1): 51–87. PMID: [8655658](https://pubmed.ncbi.nlm.nih.gov/8655658/)
58. Meesters PD, Schouws S, Stek M, de Haan L, Smit J, Eikelenboom P, et al. Cognitive impairment in late life schizophrenia and bipolar I disorder. *Int J Geriatr Psychiatry*. 2013; 28(1): 82–90. <https://doi.org/10.1002/gps.3793> PMID: [22407730](https://pubmed.ncbi.nlm.nih.gov/22407730/)
59. Weisenbach SL, Marshall D, Weldon AL, Ryan KA, Vederman AC, Kamali M, et al. The double burden of age and disease on cognition and quality of life in bipolar disorder. *Int J Geriatr Psychiatry*. 2014; 29(9): 952–61. <https://doi.org/10.1002/gps.4084> PMID: [24677268](https://pubmed.ncbi.nlm.nih.gov/24677268/)
60. Ayalon L, Arean PA, Alvidrez J. Adherence to antidepressant medications in black and Latino elderly patients. *Am J Geriatr Psychiatry*. 2005; 13(7): 572–80. <https://doi.org/10.1176/appi.ajgp.13.7.572> PMID: [16009733](https://pubmed.ncbi.nlm.nih.gov/16009733/)
61. Elliott RA, Goeman D, Beanland C, Koch S. Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review. *Curr Clin Pharmacol*. 2015; 10(3): 213–21. <https://doi.org/10.2174/1574884710666150812141525> PMID: [26265487](https://pubmed.ncbi.nlm.nih.gov/26265487/)
62. Park YH, Kim H, Jang SN, Koh CK. Predictors of adherence to medication in older Korean patients with hypertension. *Eur J Cardiovasc Nurs*. 2013; 12(1): 17–24. <https://doi.org/10.1016/j.ejcnurse.2011.05.006> PMID: [21704563](https://pubmed.ncbi.nlm.nih.gov/21704563/)
63. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? *BMC Health Serv Res*. 2012; 12: 98. <https://doi.org/10.1186/1472-6963-12-98> PMID: [22510235](https://pubmed.ncbi.nlm.nih.gov/22510235/)
64. Einstein GO, McDaniel MA. Normal aging and prospective memory. *J Exp Psychol Learn Mem Cogn*. 1990; 16(4): 717–26. PMID: [2142956](https://pubmed.ncbi.nlm.nih.gov/2142956/)

65. Kliegel M, Jager T, Altgasen M, Shum D. Clinical neuropsychology of prospective memory. In: Kliegel M, McDaniel MA, Einstein GO, editors. *Prospective Memory: Cognitive, Neuroscience, Developmental, and Applied Perspectives*. New York, NY: Taylor & Francis Group/Lawrence Erlbaum Associates; 2008. p. 283–308.
66. Simons JS, Scholvinck ML, Gilbert SJ, Frith CD, Burgess PW. Differential components of prospective memory? Evidence from fMRI. *Neuropsychologia*. 2006; 44(8): 1388–97. <https://doi.org/10.1016/j.neuropsychologia.2006.01.005> PMID: 16513147
67. Zogg JB, Woods SP, Saucedo JA, Wiebe JS, Simoni JM. The role of prospective memory in medication adherence: a review of an emerging literature. *J Behav Med*. 2012; 35(1): 47–62. <https://doi.org/10.1007/s10865-011-9341-9> PMID: 21487722
68. Lee E, Xiang YT, Man D, Au RW, Shum D, Tang WK, et al. Prospective memory deficits in patients with bipolar disorder: a preliminary study. *Arch Clin Neuropsychol*. 2010; 25(7): 640–7. <https://doi.org/10.1093/arclin/acq061> PMID: 20716545
69. Zhou JJ, Xiang YT, Wang CY, Zhou FC, Ungvari GS, Dickerson F, et al. Prospective memory deficits in euthymic bipolar disorder patients: a preliminary study. *Asia Pac Psychiatry*. 2013; 5(3): 183–90. <https://doi.org/10.1111/appy.12019> PMID: 23857635
70. Park DC, Hertzog C, Kidder DP, Morrell RW, Mayhorn CB. Effect of age on event-based and time-based prospective memory. *Psychol Aging*. 1997; 12(2): 314–27. PMID: 9189992
71. Raffaitin C, Feart C, Le Goff M, Amieva H, Helmer C, Akbaraly TN, et al. Metabolic syndrome and cognitive decline in French elders: the Three-City Study. *Neurology*. 2011; 76(6): 518–25. <https://doi.org/10.1212/WNL.0b013e31820b7656> PMID: 21288982
72. Andres P, Van der Linden M. Age-related differences in supervisory attentional system functions. *J Gerontol B Psychol Sci Soc Sci*. 2000; 55(6): P373–80. PMID: 11078107
73. Crawford JR, Bryan J, Luszcz MA, Obonsawin MC, Stewart L. The executive decline hypothesis of cognitive aging: Do executive deficits qualify as differential deficits and do they mediate age-related memory decline? *Aging, Neuropsychology, and Cognition*. 2000; 7: 9–31.
74. Frangou S, Dakhil N, Landau S, Kumari V. Fronto-temporal function may distinguish bipolar disorder from schizophrenia. *Bipolar Disord*. 2006; 8(1): 47–55. <https://doi.org/10.1111/j.1399-5618.2006.00274.x> PMID: 16411980
75. Gruber SA, Rogowska J, Yurgelun-Todd DA. Decreased activation of the anterior cingulate in bipolar patients: an fMRI study. *J Affect Disord*. 2004; 82(2): 191–201. <https://doi.org/10.1016/j.jad.2003.10.010> PMID: 15488247
76. Kronhaus DM, Lawrence NS, Williams AM, Frangou S, Brammer MJ, Williams SC, et al. Stroop performance in bipolar disorder: further evidence for abnormalities in the ventral prefrontal cortex. *Bipolar Disord*. 2006; 8(1): 28–39. <https://doi.org/10.1111/j.1399-5618.2006.00282.x> PMID: 16411978
77. Elishahawi HH, Essawi H, Rabie MA, Mansour M, Beshry ZA, Mansour AN. Cognitive functions among euthymic bipolar I patients after a single manic episode versus recurrent episodes. *J Affect Disord*. 2011; 130(1–2): 180–91. <https://doi.org/10.1016/j.jad.2010.10.027> PMID: 21074274
78. Lopez-Jaramillo C, Lopera-Vasquez J, Gallo A, Ospina-Duque J, Bell V, Torrent C, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. *Bipolar Disord*. 2010; 12(5): 557–67. <https://doi.org/10.1111/j.1399-5618.2010.00835.x> PMID: 20712758
79. Sanches M, Bauer IE, Galvez JF, Zunta-Soares GB, Soares JC. The management of cognitive impairment in bipolar disorder: current status and perspectives. *Am J Ther*. 2015; 22(6): 477–86. PMID: 25383489
80. Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. *Med Care*. 2007; 45(6): 545–52. PMID: 17515782
81. Mundry R, Nunn CL. Stepwise model fitting and statistical inference: turning noise into signal pollution. *Am Nat*. 2009; 173(1): 119–23. <https://doi.org/10.1086/593303> PMID: 19049440